
Feature|Articles|February 27, 2025
The Rapid Evolution of Multiple Myeloma Treatment in Recent Years
Author(s)Kyle Doherty
Fact checked by: Caroline Seymour
Multiple myeloma experts offer their perspectives on the evolution of the treatment landscape over the past 10 years and look towards the future of care.
Advertisement
Advertisement
Multiple myeloma, once considered a disease with a poor prognosis, has experienced a revolution in treatment over the past decade with the emergence of new approaches, such as CAR T-cell therapy and bispecific T-cell engagers. As other novel therapies progress through the development pipeline, investigators will have to consider a variety of patient-specific factors when selecting and sequencing treatments, but the future of the field is bright.
Related to this article

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

A new life-years-saved methodology found blood cancer treatments saved million years of life since 1949, with future gains reliant on funding and access.

Experts break down SOHO 2026 and topics at the meeting that will shape hematologic oncology for the rest of the year.

Etentamig improved ORR and PFS vs standard therapies in triple-class exposed relapsed/refractory multiple myeloma.

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in August 2026 spanning tumor types.

The FDA approved daraxonrasib for pancreatic cancer, cleared zanidatamab-based regimens for HER2-positive gastric cancer, and more.

An OncLive Scientific Interchange and Workshop examined community integration of bispecific antibodies in multiple myeloma.
Advertisement
Advertisement

